J&J Immunology President On Remicade, Inflectra And The Art Of Contract Negotiations

Janssen Biotech's Immunology President Scott White defended the company's Remicade contracting strategy in an interview and outlined why J&J believes it has been unfairly targeted in an anti-competitive lawsuit filed by rival Pfizer.

Man with report

Biosimilars are not small molecule generic drugs and therefore generic-like commercial dynamics should not be expected in the biosimilar market: that's the crux of Johnson & Johnson's justification for tough contract negotiations with payers for Remicade (infliximab), which rival Pfizer Inc. says have unfairly blocked its biosimilar Inflectra (infliximab-dyyb).

J&J's Janssen Biotech Immunology President Scott White talked with Scrip Oct. 11 about the commercial dynamics in the infliximab market...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip